Share Email Print
cover

Proceedings Paper

Laser immunotherapy for the treatment of human breast cancer: one-year follow up results
Author(s): Tomas Hode; Orn Adalsteinsson; Gabriela L. Ferrel; John A. Lunn; Maria C. Guerra; Xiaosong Li; Robert E. Nordquist; Wei R. Chen
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

The immediate goal of the trial was to determine the breast cancer patient tolerance and the toxicity of Laser immunotherapy (LIT), the optimal dose for the alteration of the course of the disease, and the reduction of the tumor burden. Ten stage III and IV cancer patients were treated, all of which were considered to be out of all other options. No toxicity or significant adverse reactions were observed and the treatment was well tolerated by all patients. Almost all the treated patients have had positive responses: A majority of patients experienced large-scale reduction of primary breast tumors, and all the stage IV patients experienced either complete or significant reductions in distant metastases in the lungs, liver, bone, and the brain, indicating a strong systemic effect of the treatment. We also report two cases of triple negative breast cancer patients that showed limited or no response to LIT.

Paper Details

Date Published: 24 February 2011
PDF: 10 pages
Proc. SPIE 7900, Biophotonics and Immune Responses VI, 790009 (24 February 2011); doi: 10.1117/12.874798
Show Author Affiliations
Tomas Hode, Immunophotonics, Inc. (United States)
Orn Adalsteinsson, International Strategic Cancer Alliance (United States)
Gabriela L. Ferrel, Hospital Nacional Edgardo Rebagliati Martins (Peru)
John A. Lunn, Commonwealth Medical Research Institute (Bahamas)
Maria C. Guerra, Immunophotonics, Inc. (United States)
Xiaosong Li, First Affiliated Hospital of Chinese PLA General Hospital (China)
Robert E. Nordquist, Immunophotonics, Inc.. (United States)
Wei R. Chen, Univ. of Central Oklahoma (United States)


Published in SPIE Proceedings Vol. 7900:
Biophotonics and Immune Responses VI
Wei R. Chen, Editor(s)

© SPIE. Terms of Use
Back to Top